# Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

> **NCT02195869** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 45 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02195869
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-14
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195869, "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02195869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*